<unk> , sold under the brand name Besremi, is a medication used to treat polycythemia vera. It is an interferon. It is given by injection. The most common side effects include low levels of white blood cells and platelets (blood components that help the blood to clot), muscle and joint pain, tiredness, flu-like symptoms and increased blood levels of gamma-glutamyl transferase (a sign of liver problems).<unk>  can cause liver enzyme elevations, low levels of white blood cells, low levels of platelets, joint pain, fatigue, itching, upper airway infection, muscle pain and flu-like illness. Side effects may also include urinary tract infection, depression and transient ischemic attacks (stroke-like attacks). It was approved for medical use in the European Union in February 2019, and in the United States in November 2021.<unk>  is the first medication approved by the U.S. Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera.
Ropeginterferon alfa-2b
Peginterferon alfa-2a
Peginterferon alfa-2b
Peginterferon beta-1a
Pegylated interferon
Ribavirin
Taribavirin
Telbivudine